Skip to main content
Premium Trial:

Request an Annual Quote

BioRxiv Turns One

BioRxiv, biology's answer to the physics preprint server arXiv, is turning one, writes Jocelyn Kaiser at ScienceInsider. And its developers say it's off to a good start.

"It is going really, extraordinarily well from several points of view," says John Inglis, the executive director of CSHL Press, which hosts the server. He says the volume of submissions has been high, that they are coming from biological subdisciplines that haven't previously used preprint servers, and have been of high quality.

When it started last fall, the server contained about nine papers and it now hosts some 800 papers. But as Kaiser points out, 80 new papers a month isn't much.

"Obviously, if you look at papers published in PubMed it might be 30,000 a month or something like that," Inglis says. "But there are plenty of people who a year ago were quite willing to tell me this was not a good idea and it wouldn't work. And they pointed to previous efforts to do that in biology that had clearly not worked at all. I think this is clearly different."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.